索拉非尼和沙利度胺单独及联合用药对鸡胚绒毛尿囊膜血管生成的影响

郭振亚; 叶军锋; 谢乾坤; 王广义

doi:10.3969/j.issn.1001-5256.2016.05.019

索拉非尼和沙利度胺单独及联合用药对鸡胚绒毛尿囊膜血管生成的影响

DOI: 10.3969/j.issn.1001-5256.2016.05.019

吉林大学第一附属医院肝胆胰外科

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2085
- HTML全文浏览量: 9
- PDF下载量: 463
- 被引次数: 0
出版历程
- 出版日期: 2016-05-20

Effect of sorafenib combined with thalidomide on angiogenesis in chick chorioallantoic membrane

Department of Hepatobiliary and pancreatic Surgery, The First Hospital of Jilin University

摘要

摘要:
目的探讨索拉非尼和沙利度胺单独用药及联合用药对鸡胚绒毛尿囊膜（CAM）血管生成的影响。方法采用孵化7 d的白皮种蛋做成CAM模型,随机分为空白对照组、索拉非尼组、沙利度胺组和联合用药组。加药处理后继续孵育2 d,剪取CAM并固定标本,镜下拍照,计算CAM血管覆盖率。多组间比较采用方差分析,进一步两两比较采用SNK-q检验。结果沙利度胺和索拉非尼组血管覆盖率相对于空白对照组有明显差异[（30.2±2.9）%vs（38.3±2.7）%;（26.5±2.1）%vs（38.3±2.7）%,P值均<0.05],联合用药组与沙利度胺组、索拉非尼组对比差异均有统计学意义[（12.6±1.5）%vs（30.2±2.9）%;（12.6±1.5）%vs（26.5±2.1）%,P值均<0.05]。结论索拉非尼、沙利度胺均有良好的抗血管生成作用,而联合用药可使抗血管效果更加显著。
- 血管生成抑制剂 /
- 药物筛选试验,抗肿瘤 /
- 鸡胚
Abstract:
Objective To investigate the effect of sorafenib and / or thalidomide on angiogenesis in chick chorioallantoic membrane( CAM).Methods White eggs incubated for 7 days were used to establish a CAM model. The model eggs were randomly divided blank control group,sorafenib group,thalidomide group,and sorafenib / thalidomide group. After treatment,each egg was incubated for another 2 days.The CAM samples were collected and fixed to take their pictures under a microscope,and the vascular coverage of each sample was calculated.Comparison between these groups was made by analysis of variance,and comparison between each two groups was made by SNK- q test.Results The thalidomide group or sorafenib group had significantly lower vascular coverage than the blank control group( 30. 2% ± 2. 9%or 26. 5% ± 2. 1% vs 38. 3% ± 2. 7%,P < 0. 05). The sorafenib / thalidomide group had significantly lower vascular coverage than the thalidomide group or sorafenib group( 12. 6% ± 1. 5% vs 30. 2% ± 2. 9% or 26. 5% ± 2. 1%,P < 0. 05). Conclusion Both sorafenib and thalidomide have a good anti- angiogenic effect on CAM,but a combination of the two drugs shows better efficacy.
- antiangiogenesis inhibitors /
- drug screening assays,antitumor /
- chick embryo

HTML全文

参考文献(17)

[1]FORNER A,LLOVET JM,BRUIX J.Hepatocellular careinoma[J].Lancet,2012,379(9822):1245-1255.

[2]FOLKMAN J.Angiogenesis in cancer,vascular,rheumatoid and other disrease[J].Nat Med,1995,1(1):27-31.

[3]DUAN ZX,XIE LQ.Role of the vascular endothelial growth factor signaling pathway in tumor growth and angiogenesis[J].World Chin J Dig,2010,18(27):2894-2900.(in Chinese)段泽星,谢立群.VEGF在肿瘤生长和血管生成中的作用[J].世界华人消化杂志,2010,18(27):2894-2900.

[4]WANG D,LUO L,CHEN W,et al.Significance of the vascular endothelial growth factor and the macrophage migration inhibitory factor in the progression of hepatocellular carcinoma[J].Oncol Rep,2014,31(3):1199-1204.

[5]CHOW NH,HSU PI,LIN XZ,et al.Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma:an immunohistochemical study[J].Hum Pathol,1997,28(6):698-703.

[6]PARK YN,KIM YB,YANG KM,et al.Increased expression of vascular endothelialgrowth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis[J].Arch Pathol Lab Med,2000,124(7):1061-1065.

[7]CHEN C,YU DC,TENG LS.Development of anti-tumor drugs targeting VEGF/VEGFR:a progress[J].Chin J Cancer Biother,2007,14(3):291-295,300.(in Chinese).陈川,俞德超,滕理送.以VEGF/VEGFR为靶点的抗肿瘤药物的研究进展[J].中国肿瘤生物治疗杂志,2007,14(3):291-295,300.

[8]CHENG BX,FANG X,ZHU CL,et al.Altered expression levels of miRNAs in serum of patients with hepatocellular carcinoma in the treatment of sorafenib[J].China Med Herald 2014,11(9):41-44.(in Chinese)成炳祥,方煊,朱承良,等.索拉非尼对肝癌患者血清中肿瘤相关miRNAs的影响[J].中国医药导报,2014,11(9):41-44.

[9]PERSONENI N,RIMASSA L,PRESSIANI T,et al.Molecular determinants of outcome in sorafenib treated patients with hepatocellular carcinoma[J].J Cancer Res Clin Oncol,2013,139(7):1179-1187.

[10]ZHU AX.Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012:current status and future perspectives[J].Semin Oncol,2012,39(4):493-502.

[11]PAN JQ,LU GP,YU ZJ.Thalidomide on anti-tumor research[J].Chin J Cancer Prev Treat,2012,19(7):552-555.(in Chinese)潘骥群,鲁光平,于志坚.沙利度胺抗肿瘤的研究进展[J].中华肿瘤防治杂志,2012,19(7):552-555.

[12]ALEXANIAN R,WEBER D.Thalidomide for resist and relapsing myeloma[J].Semin Hematol,2000,37(1):22-25.

[13]DAHUT WL,GULLEY JL,ARLEN PM,et al.Randomizedphase II trial of docetaxel plus thalidomide in and rogenindependent prostate cance[J].J Clin Oncol,2004,22(13):2532-2539.

[14]HUNG KC,HSIEH PM,YANG KL,et al.Effect of thalidomide on the expression of vascular endothelial growth factor in a rat model of liver regeneration[J].Oncol Lett,2013,5(3):852-856.

[15]WAINBERG ZA,DRAKAKI A.The importance of optimal drug sequencing in metastatic colorectal cancer:biological rationales for the observed survival benefit conferred by firstline treatment with EGFR inhibitors[J].Expert Opin Biol Ther,2015,15(8):1205-1220.

[16]ABOU-ALFA GK,JOHNSON P,KNOX JJ,et al.Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma:a randomized trial[J].JAMA,2010,304(19):2154-2160.

[17]SHI P.Effect of thalidomide-Gemox combination on VEGF level in patients with advanced liver cancer[J].China Prac Med,2014,9(34):134-135.(in Chinese)时沛.沙利度胺联合Gemox方案对中晚期肝癌患者VEGF水平的影响[J].中国实用医药,2014,9(34):134-135.

施引文献

资源附件(0)

访问统计